H Antagonist - Pipeline Insight, 2019 - ResearchAndMarkets.com

DUBLIN--()--The "H Antagonist - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

H Antagonist - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across H Antagonist development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for H Antagonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active H Antagonist pipeline products by developmental stage, product type, molecule type, and administration route.

Companies Featured

  • GlaxoSmithKline
  • Astellas Pharma
  • Boehringer Ingelheim
  • Boryung Pharmaceutical
  • Taiho Pharmaceutical
  • Boryung Pharmaceutical
  • Horizon Therapeutics
  • Tiltan Pharma
  • Pfizer
  • Johnson & Johnson
  • GlaxoSmithKline
  • Cyathus Exquirere
  • Servier
  • Cephalon
  • Suven Life Sciences
  • Ligand Pharmaceuticals

Topics Covered

1. Report Introduction

2. H Antagonist - Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for H Antagonist

4. Comparative Analysis

5. H Antagonist Pipeline Products in Clinical Stages

5.1 Drug Name : Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

6. H Antagonist Pipeline Products in Non-clinical Stages

6.1 Drug Name : Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment: Active Products

  • Pipeline Assessment by Route of Administration
  • Pipeline Assessment by Stage and Route of Administration
  • Pipeline Assessment by Molecule Type
  • Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

8.1 Drug Name : Company Name

  • Product Description
  • Research and Development
  • Product Development Activities
  • Reason for dormancy/discontinuation

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/jgtwms/h_antagonist?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs